Mark Cuban Cost Plus Drug Company and Coherus BioSciences are planning to offer customers Yusimry (adalimumab-aqvh), a biosimilar of AbbVie's Humira (adalimumab injection), in July 2023.
The medication is used to treat moderate to severe rheumatoid arthritis in adults.
“Humira is the top-selling medicine of all time, but for those without insurance or who are underinsured, this therapy and other biologic medicines have been out of reach due to price,” said Alex Oshmyansky, co-founder and CEO of Mark Cuban Cost Plus Drug Company. "Working with Coherus, a pioneer in the field of biosimilars, we are excited to disrupt the high-cost biologic space by offering Yusimry, a biosimilar of Humira, one of the highest cost drugs in America.”
“We believe there is a large, unmet need for improved access and affordability for patients in the U.S. healthcare system that together Cost Plus Drugs and Yusimry can help address,” said Denny Lanfear, CEO of Coherus. “This agreement is part of our biosimilar strategy to leverage our excellence in manufacturing and supply chain management to deliver safe and effective biosimilars with ensured, reliable supply.”
[Read more: Mark Cuban invests in Truepill]
Mark Cuban Cost Plus Drug Company plans to offer Yusimry to its customers for $569.27 plus dispensing and shipping fees starting in July 2023. Yusimry has a state-of-the-art autoinjector presentation that includes Coherus’ proprietary non-stinging, citrate-free formulation and a 29-gauge needle.
Yusimry also will be included in the Team Cuban Card (teamcubancard.com) prescription benefit program through participating pharmacies. The Team Cuban Card allows patients to fill prescriptions at a local independent pharmacy at the same low prices they expect from Cost Plus Drugs. In addition, the company said that the Team Cuban Card also supports the independent pharmacy community with fair dispensing fees and a transparent pricing structure.
"Cost Plus Drugs is saving patients hundreds and thousands of dollars a month by pricing our medications fairly at our cost plus 15%,” said Mark Cuban, co-founder of Mark Cuban Cost Plus Drug Company. “Adding Yusimry, a biosimilar of Humira, to Cost Plus Drugs will extend these savings to biologics. This is just our first step in making biologics affordable for patients."